Corporate ActionJul 20, 2026, 04:31 PM
Sunshine Biopharma enters $4M At-The-Market Sales Agreement
AI Summary
Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. on July 20, 2026. This agreement allows the company to sell shares of its common stock for an aggregate offering price of up to $4,000,000 through Aegis Capital Corp. as its exclusive sales agent. Aegis Capital Corp. will receive a 3.0% commission on the gross proceeds from any shares sold under the agreement.
Key Highlights
- Entered At-The-Market Issuance Sales Agreement with Aegis Capital Corp.
- Company may sell up to $4,000,000 of common stock.
- Aegis Capital Corp. to act as exclusive sales agent.
- Sales to be made in "at-the-market" offerings.
- Agent to receive 3.0% commission on gross proceeds.
- Shares will be issued pursuant to an existing Form S-3 shelf registration.
Price Impact
More from SBFM